Aclaris Therapeutics (ACRS) risk factors, FY2025 10-K

Risks Related to Our Business, Our Financial Position and Capital Needs

1. 01We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability
2. 02We will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations
3. 03Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies, intellectual property, potential future revenue streams or product candidates
4. 04We have a limited history as a clinical-stage biopharmaceutical company developing and partnering our product candidates, which may make it difficult to evaluate the success of our business to date and to assess our future viability
5. 05Certain estimates of market opportunity and forecasts may prove to be smaller than we believe

Risks Related to the Development and Potential Commercialization of Our Product Candidates

1. 06Biologics carry unique risks and uncertainties, which could have a negative impact on future results of operations
2. 07We may not be successful in our efforts to identify and develop additional product candidates, including through leveraging our KINect drug discovery platform91% rewritten
3. 08The rapid advancement of artificial intelligence and computational drug discovery technologies could make our KINect platform and discovery approaches less competitive or obsolete, and our failure to successfully adopt and integrate artificial intelligence technologies could put us at a competitive disadvantageNew
4. 09If we are unable to successfully develop our product candidates and identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our product candidates, or experience significant delays in doing so, our business will be harmedNew
5. 10If we experience delays or difficulties in the enrollment of subjects in clinical trials, our ability to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our product candidates could be delayed or preventedNew
6. 11their performance. Any delays in completing clinical trials would delay or prevent our ability to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our product candidatesNew
7. 12Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more subject data become available and are subject to audit and verification procedures that could result in material changes in the final data
8. 13Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
9. 14We have conducted and may in the future conduct clinical or nonclinical studies for our product candidates outside the United States. The FDA, EMA or comparable foreign regulatory authorities may not accept data from such studies24% rewritten
10. 15We may not be successful in our efforts to increase our pipeline of product candidates, including by in-licensing or acquiring additional product candidates
11. 16We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
12. 17For any of our product candidates that receive marketing approval, our potential third-party partners may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
13. 18We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do93% rewritten
14. 19in the future, from many different sources, including major pharmaceutical, biotechnology and specialty pharmaceutical companies, academic institutions and governmental agencies and public and private research institutionsNew
15. 20The success of our product candidates, if approved, will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these products64% rewritten
16. 21legislation will impact our business, and any changes in coverage and reimbursement that further restricts coverage of our product candidates could harm our businessNew

Risks Related to Our Dependence on Third Parties

1. 22We rely on third parties to conduct clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials91% rewritten
2. 23of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to earn revenue from those partnerships could be delayed significantlyNew
3. 24We intend to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our product candidates. If those arrangements are not successful, we may not be able to capitalize on the market potential of these product candidatesNew
4. 25Our development programs for our product candidates will require substantial additional capital. We intend to partner with pharmaceutical and biotechnology companies for the further development and/or commercialization of our product candidates
5. 26We are dependent on third parties accurately generating and reporting data related to our product candidates, and their conduct could adversely affect our business

Risks Related to Our Intellectual Property

1. 27Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates
2. 28We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court
3. 29We may not be able to protect our intellectual property rights throughout the world28% rewritten
4. 30We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
5. 31Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
6. 32We may be subject to claims by third parties asserting that we, our employees or our licensors have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property
7. 33Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
8. 34If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
9. 35The validity, scope and enforceability of any of our patents that cover any of our product candidates can be challenged by competitors
10. 36If we do not obtain protection under the Hatch-Waxman Act by extending the patent term and obtaining data exclusivity for our product candidates, our business may be materially harmed29% rewritten
11. 37protection afforded could be less than we request. Similar provisions are available in certain foreign countries, such as the European Union and JapanNew
12. 38Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business
13. 39Outside of the United States we cannot be certain that any country’s patent or trademark office will not implement new rules that could seriously affect how we draft, file, prosecute and maintain patents, trademarks and patent and trademark applications
14. 40Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters

1. 41If our potential third-party partners are not able to obtain, or if there are delays in obtaining, required regulatory approvals, our product candidates will not be able to be commercialized, and our ability to earn revenue from arrangements with such third-party partners will be materially impaired
2. 42Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad
3. 43A variety of risks associated with marketing our product candidates by our potential third-party partners internationally could harm our business
4. 44These and other risks associated with international operations may compromise our ability to earn revenue from arrangements with potential third-party partners for our product candidates
5. 45Recently enacted and future legislation may increase the difficulty and cost for our potential third-party partners to obtain marketing approval of our product candidates and commercialize our product candidates, if approved, and affect the prices our potential third-party partners may obtain72% rewritten
6. 46Our biological product candidates may face competition sooner than anticipated
7. 47Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue
8. 48If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business36% rewritten
9. 49and penalties. If notwithstanding our efforts to comply with these laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmedNew
10. 50We are subject to governmental economic sanctions laws and export and import controls that could impair our potential third-party partners’ ability to compete in international markets or subject us or our potential third-party partners to liability if we or they are not in compliance with applicable laws81% rewritten
11. 51We and our potential third-party partners are subject to anti-corruption and anti-money laundering laws with respect to our and their operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business

Risks Related to Employee Matters and Managing Our Growth

1. 52Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel
2. 53Our employees, independent contractors, consultants, third-party partners, principal investigators, CROs and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements

Risks Related to Ownership of Our Common Stock

1. 54The trading price of the shares of our common stock has been and is likely to continue to be volatile
2. 55If we fail to maintain compliance with the listing requirements of the Nasdaq Global Select Market, we may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted
3. 56Sales of a substantial number of shares of our common stock into the market could cause the market price of our common stock to drop significantly, even if our business is doing well
4. 57Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result
5. 58If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
6. 59We might not be able to utilize a significant portion of our net operating loss carryforwards and research and development tax credit carryforwards49% rewritten
7. 60We do not anticipate paying any cash dividends on our common stock in the foreseeable future and our stock may not appreciate in value
8. 61Exclusive forum provisions in our amended and restated certificate of incorporation and amended and restated bylaws could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees
9. 62Our holders of 5% or more of our capital stock collectively own a significant percentage of our outstanding common stock and have the ability to exert significant control over matters subject to stockholder approval
10. 63We are a “smaller reporting company” and, as a result of the reduced disclosure and governance requirements applicable to smaller reporting companies, our common stock may be less attractive to investors41% rewritten
11. 64these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to develop our product candidates and provide our servicesNew
12. 65An active trading market for our common stock may not be sustained
13. 66If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
14. 67Unfavorable macroeconomic conditions, including tariff policies and inflationary pressure, as well as constrained capital markets, could limit our ability to grow our business, raise capital and negatively affect our operating resultsNew
15. 68The issuance of additional stock in connection with financings, acquisitions, investments, our equity incentive plan or otherwise will dilute all other stockholders
16. 69Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations57% rewritten
17. 70We incur significant costs and demands upon management as a result of being a public company49% rewritten
18. 71Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data, and may subject us to evolving regulatory requirementsNew